A Phase â…¡ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
Evaluate the efficacy and safety of RC108 in combination with Furmonertinib against Furmonertinib for treatment of EGFR mutation combined with MET-positive unresectable locally advanced or recurrent metastatic NSCLC
Non-Small Cell Lung Cancer
DRUG: RC108|DRUG: Furmonertinib Mesilate Tablets Monotherapy
Objective Response Rate (ORR), Investigator-assessed ORR, 24 months
Progression-free survival (PFS), Investigator-assessed PFS, 24 months|Disease Control Rate (DCR), Investigator-assessed DCR, 24 months|Duration of Response (DoR), Investigator-assessed DoR, 24 months|Overall survival (OS), Investigator-assessed OS, 45 months|Number of participants with adverse events (AEs), An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment., 24 months|Incidence of RC108 anti-drug antibody (ADA), Incidence, occurrence time and ADA titer of positive RC108 ADA and neutralizing antibodies, 24 months|Pharmacokinetic profile of RC108, Peak and trough concentrations of RC108 total antibody (TAb), conjugated antibody (ADC), free MMAE, 24 months
Primary objective: Evaluate the efficacy and safety of RC108 in combination with Furmonertinib against Furmonertinib for treatment of EGFR mutation combined with MET-positive unresectable locally advanced or recurrent metastatic NSCLC Secondary objective: Evaluate the pharmacokinetic and immunogenicity characteristics of RC108 in combination with Furmonertinib